Top sto­ries of the week: Thumbs up/Thumbs down

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Cel­gene taps its new biotech co-star

This was the per­fect week to an­swer a ques­tion I’ve been think­ing about re­gard­ing Cel­gene. The Big Biotech, which has spe­cial­ized in lin­ing up rich deals for star col­lab­o­ra­tors, has set­tled on Jounce as its lat­est pick for up-and-com­ing biotech with the most po­ten­tial. Cel­gene has been stitch­ing to­geth­er a whole pipeline of im­muno-on­col­o­gy drugs through its BD team, head­ed by George Golumbes­ki. Our chart on all its pacts, and the $3.2 bil­lion it spent on deals over the past two years, proved to be the most pop­u­lar part of the week. Those deals al­so il­lus­trate how in­dus­try part­ner­ships dri­ve new pro­grams. Im­por­tant point: It’s not over at Cel­gene.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER